Cargando…
Interferon α may be back on track to treat acute myeloid leukemia
Our own experience and a thorough literature review suggest that interferon α (IFNα) should be reconsidered for the treatment of acute myeloid leukemia patients. Most likely, the success of such treatment depends on the achievement of high serum levels of IFNα for several months, which can be obtain...
Autores principales: | Smits, Evelien L.J.M., Anguille, Sébastien, Berneman, Zwi N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654584/ https://www.ncbi.nlm.nih.gov/pubmed/23734314 http://dx.doi.org/10.4161/onci.23619 |
Ejemplares similares
-
CD56 marks human dendritic cell subsets with cytotoxic potential
por: Roothans, Dessie, et al.
Publicado: (2013) -
Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties
por: Anguille, Sébastien, et al.
Publicado: (2009) -
Interferons in hematopoiesis and leukemia
por: Schürch, Christian M, et al.
Publicado: (2013) -
IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia
por: Ilander, Mette, et al.
Publicado: (2014) -
Interferon α interferes with immunological tolerance
por: Becker, Christian, et al.
Publicado: (2013)